Yichang Renfu Pharmaceutical's Lumiracoxib Capsules (Toluene Sulfonate) Approved for Clinical Trials
Time：
2025-03-31
Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the conduct of clinical trials of lumeperone tosylate capsules for adult schizophrenia. This product is classified as a Class 3 chemical drug, and currently there are no similar products on the market in China.
Recently, Yichang Renfu Pharmaceutical Co., Ltd. received a "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, agreeing to conduct clinical trials of lumeperlone tosilate capsules for the treatment of schizophrenia in adults. This product is classified as a Class 3 chemical drug, and there are currently no similar products on the market in China.
Lumeperlone is a novel antipsychotic drug with a multi-target effect, exerting its therapeutic effect by simultaneously regulating the 5-hydroxytryptamine (5-HT), dopamine (DA), and glutamate neurotransmitter pathways. It was approved by the U.S. FDA in 2019 for the treatment of schizophrenia in adults and in 2021 for the treatment of depressive episodes associated with Type I or Type II bipolar disorder in adults.
The development of lumeperlone tosilate capsules is an important strategic move by Yichang Renfu in the research and development of drugs for mental disorders. After receiving the notice of approval for drug clinical trials, the company will start the relevant work, and after completing the clinical research, it will submit an application for market authorization to bring relief to patients suffering from mental illness as soon as possible.
Tags:
Related News
ABOUT US
CONTACT
Add：66 Tianjiahe Avenue, Baiyang Town, Baiyang,Industrial Park, High-tech Zone,Yichang City, Hubei Province, China.
Tel：+86-717-4065884 +86-717-4065888
E-mail：yctr@renfu.com.cn
Copyright © 2024 YICHANG TIANRUI BIOPHARM CO., LTD All Rights Reserved.